Even as drug makers applauded the reemergence of FDA guidance on post-approval changes for drug substances, they criticized the prescriptive nature of the guidance document the agency drafted.
The draft guidance is out of keeping with international drug quality principles that have emerged since the agency withdrew the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?